Resistance to Herceptin (trastuzumab) in HER2 positive breast cancers: the role of calcium signalling.

HER2 阳性乳腺癌对赫赛汀（曲妥珠单抗）的耐药性：钙信号传导的作用。

• 批准号: nhmrc : 1079672
• 负责人: Prof Gregory Monteith
• 金额: $ 41.36万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/resistance-herceptin-trastuzumab-calcium-signalling/518688
• 关键词: Resistance; Herceptin; trastuzumab; HER2; positive

The monoclonal antibody therapy trastuzumab has revolutionized the treatment of women with Her2 positive breast cancer. Unfortunately some Her2 positive breast cancers do not respond to this therapy or gradually develop resistance. This project will define how an important cellular signal is remodeled in breast cancers resistant to trastuzumab. The ability of modulators of this signaling pathway to alter the sensitivity of breast cancers to trastuzumab will also be determined.

单克隆抗体疗法曲妥珠单抗彻底改变了Her2阳性乳腺癌女性的治疗。不幸的是，一些Her2阳性乳腺癌对这种疗法没有反应或逐渐产生耐药性。该项目将定义一个重要的细胞信号如何在对曲妥珠单抗耐药的乳腺癌中重塑。还将确定该信号传导途径的调节剂改变乳腺癌对曲妥珠单抗的敏感性的能力。